Clinical Trial Results:
Liraglutide Effect and Action in Diabetes (LEAD-5): Effects on glycaemic control after once daily administration of liraglutide in combination with glimepiride and metformin versus glimepiride and metformin combination therapy, and versus insulin glargine added to glimepiride and metformin combination therapy in subjects with type 2 diabetes.
A six-month randomised, double-blind, parallel-group, multi-centre, multi-national trial with an open-label treat-to-target insulin glargine control arm
Summary
|
|
EudraCT number |
2005-003415-71 |
Trial protocol |
AT GB SK FI DK IT |
Global completion date |
20 Apr 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Feb 2016
|
First version publication date |
18 Mar 2014
|
Other versions |
|
Summary report(s) |
Synopsis – Including CTR Amendment 1, Dated 28 May 2009 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.